More specifically, AML subgroups including APL, core binding factor (CBF) AML, and NPM1-mutated AML should be monitored by RT-qPCR, whereas the use of MFC is strongly recommended in all other AML subgroups (23, 24). This evidence concerns the gene CEBPZ and acute myeloid leukemia.